Hikma Pharmaceuticals PLC (HIK.L)

1,981.00 +8.00 (+0.41%) 收市：04:35PM BST

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
https://www.hikma.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 9,100

高階主管

名稱	頭銜	支付	行使價	出生年份
Engineer Said Samih Taleb Darwazah	Executive Chairman	2.24M	無	1957
Mr. Riad Ali Mishlawi	CEO & Director	882.88k	無	1964
Mr. Mazen Samih Taleb Darwazah	Executive Vice Chairman & President of MENA	1.84M	無	1958
Mr. Khalid Waleed Hosny Al Nabilsi	Chief Financial Officer	無	無	1972
Patricia Bousfield	Chief Information Officer	無	無	無
Mr. Guy Featherstone	Associate Director of Investor Relations	無	無	無
Mr. Samuel Park	General Counsel	無	無	無
Mr. Bassam Wael Rushdi Kanaan CFA, CPA	Executive Vice President of Corporate Development and M&A	無	無	1965
Mr. Hussein Omar Arkhagha	Chief People Officer	無	無	無
Ms. Susan Ringdal	Executive Vice President of Strategic Planning & Global Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 GBp。

描述

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

公司管治

截至 2024年5月1日 止，Hikma Pharmaceuticals PLC 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：6；董事會：5；股東權利：1；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。